Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that new sub-analyses of data relating to Lyxumia® (lixisenatide) and new preclinical data relating to ZP3022, a compound from Zealand’s proprietary GLP-1-gastrin dual acting receptor agonist program for the potential treatment of diabetes, will be presented at the European Association for the Study of Diabetes (EASD) 49th Annual Meeting on 23 – 27 September 2013 in Barcelona, Spain. Lyxumia® (lixisenatide), discovered by Zealand and licensed globally to Sanofi, is the first once-daily prandial GLP-1 receptor agonist marketed for the treatment of adults with type 2 diabetes.
Help employers find you! Check out all the jobs and post your resume.
